Please assess the completion status of the following clinical trial:

Trial Title: Edoxaban Versus Edoxaban With antiPlatelet Agent In Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. A subject was ≥ 18 years of age~2. Patients with nonvalvular atrial fibrillation with high embolic risk (CHA2DS2-VASc score ≥2)~3. Patients with Stable coronary artery disease~   * Anatomically confirmed coronary artery disease (with ≥50% stenosis of major epicardial coronary artery documented by cardiac catheterization or coronary computed tomographic angiography) on medical therapy alone.~  * Revascularized coronary artery disease (either Percutaneous Coronary Intervention or coronary bypass surgery) whom the last revascularization should be performed ≥12 months before study enrollment for the acute coronary syndrome and ≥6 months for stable angina pectoris.~Exclusion Criteria~1. Patients with thrombocytopenia~2. High risk of bleeding which prohibits the anticoagulant use. (baseline comorbidities, hyper or hypercoagulable state, increased prothrombin time or activated partial thromboplastin time)~3. Prior history of intracranial haemorrhage~4. Mechanical prosthetic valve or moderate to severe mitral stenosis~5. The risk of bleeding increased due to the following reasons;~   * i. history of gastrointestinal ulcers within 1 month~  * ii. Malignant tumor with high risk of bleeding~  * iii. Brain or spinal cord injury within 1 month~  * iv. History of intracranial or intracerebral hemorrhage within 12 months~  * v. Esophageal varices~  * vi. Spinal cord vascular abnormalities or intracerebral vascular abnormalities~  * vii. Active bleeding~  * viii. Hemoglobin level \<7.0 g/dL or platelet count ≤ 50,000 / mm3~  * ix. History of major surgery within 1 month~6. Uncontrolled severe hypertension~7. Hemodynamically Unstable or pulmonary embolism requiring thrombolysis or pulmonary embolectomy~8. History of hypersensitivity to Edoxaban, aspirin, or clopidogrel~9. Genetic problem with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption~10. Planned Percutaneous Coronary Intervention or coronary bypass surgery was planned within 1 year after randomization~11. Liver cirrhosis or liver dysfunction (AST or ALT \> x3 of normal range or coagulation abnormality)~12. Estimated CrCl by Cockcroft-Gault equation\<15 mL/min~13. Life expectancy less than 12 months~14. The subject was unable to provide written informed consent or participate in long-term follow-up~15. Pregnant and/or lactating women~16. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edoxaban alone (Type: EXPERIMENTAL): None
- Combination of edoxaban plus single antiplatelet (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).